2 recruiting, 1 terminated. 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Acute Lymphoblastic Leukemia Not Having Achieved Remission: new trials by email Literature Review of Acute Lymphoblastic Leukemia Not Having Achieved Remission trials Research Report on Acute Lymphoblastic Leukemia Not Having Achieved Remission
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia MB-CART19.1 - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Recurrent | Not applicable | Recruiting | King Hussein Cancer Center | 12 | 2026-02-20 | 2026-08-05 |
| Determining the Mechanisms of Loss of CAR T Cell Persistence Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission | Recruiting | University College, London | 50 | 2023-10-18 | 2026-08-07 | |
| CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Terminated | Medical College of Wisconsin | 5 | 2020-10-16 | 2026-01-12 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3)
King Hussein Cancer Center (1) · Medical College of Wisconsin (1) · University College, London (1)
Jordan (1) · United Kingdom (1) · United States (1)
Dr Zaid Abdel Rahman, Consultant,Hematology/Oncology (1) · Dr. Hasan Hashem, Consultant,Hematology/Oncology (1) · Julie-An Talano, MD (1) · Persis Amrolia, BSc,MBBS,PhD (1)